Health
## NHS Rolls Out £3,000 GP Bonus to Boost Mounjaro Prescriptions Amidst Tight Eligibility
**ENGLAND** – General Practitioners (GPs) across England are set to receive a £3,000 bonus under a new initiative designed to significantly increase the prescription of Mounjaro, a prominent weight loss medication. The move, spearheaded by NHS England, aims to improve patient access to the drug, though medical experts are cautioning that strict eligibility criteria will continue to limit its widespread availability.
The incentive scheme offers a one-off payment to GP practices that effectively “maximise” the initiation of Mounjaro prescriptions for eligible patients. While specific targets have not been fully disclosed, the underlying goal is to leverage primary care’s reach to address the escalating public health challenge of obesity.
Mounjaro, known generically as tirzepatide, is an injectable medication that works by mimicking natural hormones to suppress appetite and regulate blood sugar. Clinical trials have demonstrated its significant efficacy in weight reduction, leading to its approval for use in adults with a Body Mass Index (BMI) of 30 or higher, or 27 or higher in the presence of at least one weight-related comorbidity such as type 2 diabetes or high blood pressure.
The rollout of Mounjaro through primary care forms part of a broader strategy to expand the NHS’s capacity to manage obesity, a condition linked to numerous serious health issues including cardiovascular disease, certain cancers, and musculoskeletal problems. Historically, access to such potent weight loss drugs has often been restricted to specialist weight management services, contributing to long waiting lists and delayed interventions.
However, despite the drive to boost prescriptions, medical experts and patient advocates have quickly highlighted that the eligibility for Mounjaro remains tightly controlled. Guidelines from the National Institute for Health and Care Excellence (NICE) stipulate precise criteria, demanding a high BMI and specific co-existing conditions, alongside a commitment to a comprehensive weight management programme that includes diet and exercise. This means that while more GPs may be empowered to prescribe, the pool of eligible patients will remain relatively small and defined by clinical need, not general demand.
Critics suggest that while the incentive is a positive step for raising awareness and potentially streamlining the prescription process for *eligible* individuals, it does not fundamentally alter the strict clinical gatekeeping required. Concerns have also been voiced about the potential for public misunderstanding regarding who can realistically expect to receive the drug, given the tight restrictions.
As the scheme progresses, its effectiveness will likely be measured not only by the increase in prescriptions but also by its success in improving health outcomes for those most in need, all while navigating the complexities of drug availability and strict clinical guidance.
